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Scedosporium infections are rare complications in immunocompromised patients or patients with chronic pulmonary disease. While Scedosporium
prolificans is resistant to most antimycotics, Scedosporium apiospermum is usually sensitive to voriconazole and posaconazole. Pharmacokinetics and
efﬁcacy of nebulized voriconazole have been described in a murine model previously. We report for the ﬁrst time the safe and effective use of nebulized
voriconazole for the treatment of severe pulmonary infection with Scedosporium apiospermum in an adolescent with cystic fribrosis.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Scedosporium apiospermum; Cystic ﬁbrosis; Antimycotic treatment; Fungal infectionsInfections due to Scedosporium species in humans are rare and
caused predominantly by S. apiospermum and S. prolificans.
Invasive infections are mainly seen in immunodeficient patients,
due to chronic steroid use, hematopoietic stem cell or solid
organ transplantation or hematological malignancy. Predomi-
nantly not only the lungs, but also other sites of infection, for
example, the central nervous system, bones and joints may be
affected [1]. Moreover invasive pulmonary infections may also
be rare complications in immune competent patients with chronic
pulmonary disease [2].
Invasive fungal infections of the lung typically present with
fever, productive cough, hemoptysis, tachypnea and malaise.
Diagnostic criteria include clinical and radiological findings and
furthermore histopathological examination, culture, molecular
technologies and serology [1].
Therapy is difficult, as common antifungal drugs have varying
levels of activity against S. apiospermum. S. prolifcans is usually
resistant to most antifungal drugs. A large retrospective study
provides support for the use of voriconazole for the treatment of
infections with S. apiospermum [3].⁎ Corresponding author Tel.: +49 731 500 57230; fax: +49 731 500 57334.
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http://dx.doi.org/10.1016/j.jcf.2013.10.014We report the case of a seventeen year old patient with cystic
fibrosis and severe respiratory failure due to an infection
with S. apiospermum. Initially the patient had stable lung
function with a forced exspiratory volume (FEV1) of 60% and
a chronic colonization with Stenotrophomonas maltophilia and
Staphylococcus aureus. Secondary to clinical worsening, a
drop in lung function (FEV1 of 40%) and a rise in aspergillus
antibodies and IgE levels (maximum 3499 kU/l) without detection
of aspergillus antigen in the blood, the patient was suspected to
have allergic bronchopulmonary aspergillosis (ABPA) and was
treated accordingly with prednisolone (2.0 mg/kg body weight
per day for 14 days, followed by a slow taper) and itraconazole
(200 mg twice daily). After 4 weeks his clinical condition
worsened significantly, accompanied by a rise in inflammatory
parameters and hemoptysis. Within 2–3 days he developed
respiratory failure type two with hypercapnia, hypoxia and oxygen
requirement of up to 5–6 l/min via nasal prongs and a further drop
of FEV1 to 19%.While the chest X-ray demonstrated new bilateral
infiltrates, the CT scan of the chest revealed severe cavernous
pulmonary destruction (Fig. 1A). Finally S. apiospermum was
isolated from bronchoalveolar lavage (BAL) and identified by
sequencing 18S ribosomal RNA. In BAL and several sputum
specimens, no other microorganism, which could have explained
this respiratory deterioration, was detected.by Elsevier B.V. All rights reserved.
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and caspofungin with a minimum inhibitory concentration (MIC)
higher than 32 μg/ml, intermediate resistant against amphotericin
B (MIC 2 μg/ml) and sensitive against voriconazole with a MIC
of less than 0.047 μg/ml. These breakpoints were determined due
to our experience with MIC values of antifungal agents in
other invasive fungal infections, for example infections due to
Candida species or Aspergillus species. S. apiospermum had been
detected in the patient sputum occasionally 3 years prior to his
deterioration.
Systemic treatment with parenteral voriconazole (8 mg/kg
body weight per day in two doses) and liposomal amphotericin
B (3 mg/kg body weight per day once daily) was startedFig. 1. Initial CT-scan of the chest revealed severe cavernous pulmonary
destruction (A). After 3 weeks of parenteral treatment with voriconazole and
liposomal amphotericin B infiltrates still increased on the CT-scan (B). After
adding nebulized treatment with voriconazole to its systemic application, six
weeks later his clinical condition and the CT-scan improved (C).intravenously without improvement of his clinical condition.
After 3 weeks, in a follow up CT scan of the chest even an
aggravation of the cavernous destruction was seen (Fig. 1B).
Confronted with the severity of the disease, the literature was
reviewed for further treatment options.
In animal models with invasive pulmonary aspergillosis
improved survival had been reported when both inhaled and
systemic amphotericin B was administered, compared to systemic
administration alone [4]. Some investigators described the
prophylactic nebulization of amphotericin B in immunodeficient
patients, for example after lung transplantation. However, due to
small numbers, there is still insufficient data to determine the
effectiveness of such a treatment and to recommend its routine use
[5,6].
Characterization and pharmacokinetics of aerosolized aqueous
voriconazole solution has been described recently by Tolman et
al. [7,8]. Voriconazole, dissolved with sulfobutyl ether-β-
cyclodextrin, is commercially available as Vfend® for intrave-
nous use. Reconstituted with sterile water to a concentration of
6.25 mg/ml voriconazole and 100 mg/ml sulfobutyl ether-β-
cyclodextrin, the solution is isotonic with a mass median
aerodynamic diameter of 2.98 μm and a fine particle fraction of
71.7% [7], suggesting an appropriate distribution of the nebulized
droplets also into more distal areas of the lung. In mice, high lung
deposition as well as an increase in plasma concentrations was
observed, following single and multiple inhaled doses [7]. In a
murine model with immunocompromised animals with invasive
pulmonary aspergillosis, mice that were prophylactically nebu-
lized with voriconazole had a survival advantage over controls
and even those treated with amphotericin B intraperitoneally [8].
Based on these data, we started a treatment with nebulized
voriconazole (Vfend®, 40 mg, once daily) in addition to systemic
application in order to reach maximum drug concentrations in
the lungs. The additional treatment with nebulized voriconazole
was very well tolerated without any side effects, especially no
increased airway obstruction. Drug plasma concentration of
voriconazole was measured before and after parenteral and also
after nebulized application of voriconazole. No toxic increase of
drug plasma concentration after nebulization could be detected
and peak plasma levels ranged between 1500 and 5000 μg/l.
Additional treatment with omeprazole, which was initially
administered because of hemoptysis, did not influence the plasma
level of voriconazole significantly and no dose modification was
necessary.
The patient's respiratory situation improved already two
weeks after the start of voriconazole nebulization. In the
following months, further respiratory stabilization (FEV1 of
30% with minimal oxygen requirement) and regression of the
infection also on follow up CT-scans (Fig. 1C) was achieved.
The nebulizations and the intravenous treatment were contin-
ued until successful lung transplantation 3 months later. In
follow up investigations S. apiospermum was detected only
once in secretions from the nostrils shortly after transplantation,
but it was not detected in several bronchoalveolar lavages
afterwards. Oral voriconazole was continued (400 mg twice
daily) for another year post transplantation and despite
immunosupression, no relapse of the Scedosporium infection
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is currently still in stable respiratory situation (FEV1 of 80%)
without any signs of bronchiolitis obliterans.
To our knowledge this is the first report of the safe and
effective use of nebulized voriconazole in addition to systemic
application for the treatment of severe pulmonary infection
with S. apiospermum in a patient with cystic fribrosis. After
we had treated our patient with nebulized voriconazole,
recently also Hilberg et al. reported three patients with
invasive, pulmonary aspergillosis who had been successfully
treated with inhaled voriconazole alone because of severe side
effects of systemic treatment [9].
Although there is still limited experience, nebulized applica-
tion of voriconazole as described above, seems to be a safe
treatment option in patients with severe fungal infections,
where exclusive systemic application is not sufficient or not
tolerated because of side effects. Larger clinical trials and further
investigations will be necessary to prove the efficacy of nebulized
voriconazole in the treatment of pulmonary fungal infections.
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